ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone201-478-5552
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$16.99 million
Profitability
Miscellaneous
Employees314
Next Earnings Date11/14/2019 (Estimated)
OptionableOptionable
ADMA Biologics (NASDAQ:ADMA) Frequently Asked Questions
What is ADMA Biologics' stock symbol?
ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."
How were ADMA Biologics' earnings last quarter?
ADMA Biologics Inc (NASDAQ:ADMA) posted its quarterly earnings data on Thursday, August, 8th. The biotechnology company reported ($0.25) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.29) by $0.04. The biotechnology company earned $6.56 million during the quarter, compared to analyst estimates of $4.36 million. ADMA Biologics had a negative net margin of 323.54% and a negative return on equity of 214.26%. View ADMA Biologics' Earnings History.
When is ADMA Biologics' next earnings date?
What price target have analysts set for ADMA?
7 brokerages have issued 12-month price objectives for ADMA Biologics' stock. Their forecasts range from $4.00 to $14.00. On average, they expect ADMA Biologics' stock price to reach $10.1667 in the next year. This suggests a possible upside of 151.7% from the stock's current price. View Analyst Price Targets for ADMA Biologics.
What is the consensus analysts' recommendation for ADMA Biologics?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ADMA Biologics.
What are Wall Street analysts saying about ADMA Biologics stock?
Here are some recent quotes from research analysts about ADMA Biologics stock:
- 1. HC Wainwright analysts commented, "We note that Perceptive Credit Holdings is an investment entity of Perceptive Life Advisors, which is one of ADMA’s largest institutional shareholders. In our view, Perceptive’s extension of credit to ADMA underscores the investor’s confidence in the company." (2/21/2019)
- 2. Maxim Group analysts commented, "ADMA announced that FDA has accepted the BLA resubmission for RI-002, the company’s specialized IVIG immunoglobulin for Primary Immune Deficiency Disease (PIDD) and assigned a PDUFA date on April 2, 2019." (10/17/2018)
Has ADMA Biologics been receiving favorable news coverage?
Headlines about ADMA stock have been trending positive recently, InfoTrie reports. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. ADMA Biologics earned a media sentiment score of 2.5 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 6.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the stock's share price in the immediate future. View News Stories for ADMA Biologics.
Who are some of ADMA Biologics' key competitors?
Some companies that are related to ADMA Biologics include Twist Bioscience (TWST), NanoString Technologies (NSTG), BAVARIAN NORDIC/S (BVNRY), Rubius Therapeutics (RUBY), Vericel (VCEL), Voyager Therapeutics (VYGR), MeiraGTx (MGTX), Atara Biotherapeutics (ATRA), Krystal Biotech (KRYS), Adverum Biotechnologies (ADVM), Cortexyme (CRTX), Osiris Therapeutics (OSIR), GENFIT S A/ADR (GNFT), DBV TECHNOLOGIE/S (DBVT) and Cellectis (CLLS).
What other stocks do shareholders of ADMA Biologics own?
Who are ADMA Biologics' key executives?
ADMA Biologics' management team includes the folowing people:
- Mr. Adam S. Grossman, Co-Founder, Pres, CEO & Director (Age 42)
- Dr. Jerrold B. Grossman Ph.D., D.P.S., Co-Founder & Vice Chairman (Age 71)
- Mr. Brian Lenz CPA, CPA, Exec. VP & CFO (Age 47)
- Dr. James Mond, Exec. VP, Chief Scientific Officer & Chief Medical Officer (Age 73)
- Mr. James Hauert, Sr. VP of Commercialization & Strategy
Who are ADMA Biologics' major shareholders?
ADMA Biologics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Perceptive Advisors LLC (19.42%), Vanguard Group Inc. (4.25%), BlackRock Inc. (3.29%), Jefferies Group LLC (1.33%), Morgens Waterfall Vintiadis & Co. Inc. (0.95%) and Northern Trust Corp (0.52%). Company insiders that own ADMA Biologics stock include Adam S Grossman, Biotest Divestiture Trust, Brian Lenz, Eric I Richman, James Mond, Jerrold B Grossman, Lawrence P Guiheen and Life Sciences Maste Perceptive. View Institutional Ownership Trends for ADMA Biologics.
Which institutional investors are selling ADMA Biologics stock?
Which institutional investors are buying ADMA Biologics stock?
ADMA stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, BlackRock Inc., Vanguard Group Inc., Jefferies Group LLC, Marshall Wace North America L.P., A.R.T. Advisors LLC, Ardsley Advisory Partners LP and Northern Trust Corp. Company insiders that have bought ADMA Biologics stock in the last two years include Adam S Grossman, Brian Lenz, Eric I Richman, James Mond, Jerrold B Grossman, Lawrence P Guiheen and Life Sciences Maste Perceptive. View Insider Buying and Selling for ADMA Biologics.
How do I buy shares of ADMA Biologics?
Shares of ADMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ADMA Biologics' stock price today?
One share of ADMA stock can currently be purchased for approximately $4.04.
How big of a company is ADMA Biologics?
ADMA Biologics has a market capitalization of $239.65 million and generates $16.99 million in revenue each year. The biotechnology company earns $-65,740,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis. ADMA Biologics employs 314 workers across the globe.View Additional Information About ADMA Biologics.
What is ADMA Biologics' official website?
How can I contact ADMA Biologics?
ADMA Biologics' mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The biotechnology company can be reached via phone at 201-478-5552 or via email at [email protected]
MarketBeat Community Rating for ADMA Biologics (NASDAQ ADMA)
MarketBeat's community ratings are surveys of what our community members think about ADMA Biologics and other stocks. Vote "Outperform" if you believe ADMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADMA will underperform the S&P 500 over the long term. You may vote once every thirty days.
